For information only. Not investment advice, a recommendation, an offer or a solicitation, and without regard to any recipient’s objectives or circumstances. Figures come from third-party sources believed reliable but not guaranteed, and market data may be delayed. Past performance is not a reliable indicator of future results. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() Vertex Pharmaceuticals IncorporatedVRTX US · Health Care · USD Current price$519.69as of Nov 19, 2026 Summary
Analyst consensusStrong Buy 6Buy 20Hold 5Sell 128 analysts 3-year price (USD)Factor profileMulti-factor score 85 / 100 Market data
Business descriptionVertex Pharmaceuticals discovers and develops small-molecule and cell therapies, led by a dominant franchise in cystic fibrosis (Trikafta and predecessor CF modulators) and expanding into non-opioid pain, sickle cell disease, kidney disease (IgA nephropathy), type-1 diabetes, and — via the proposed Crinetics acquisition — rare endocrine disease. It is a rare example of a large-cap biotech with a near-monopoly in its base indication and a multi-front pipeline optionality story. Competitive moatVertex owns the cystic fibrosis market outright: its CF modulators are the only disease-modifying therapies approved for the underlying protein defect, creating a durably priced franchise with essentially no generic or biosimilar substitution risk and a patient population that expands as label ages and genotypes broaden. The moat is now being extended rather than defended — Journavx (a peripherally acting non-opioid painkiller that blocks pain signalling before it reaches the brain) has no addictive potential, which is a structural differentiator versus opioids and could drive rapid share gains in acute pain. Casgevy, a one-time functional cure for sickle cell disease, adds a curative (higher-value, one-shot) model. A debt-free balance sheet and 2.65 current ratio fund pipeline investment and the Crinetics deal. Recent developments
Investment risks / red flags
Financials
Classification
|
Factor Profile (Spider Chart)
TBI ModelPrice Chart (TradingView)
Symbol: VRTXBusiness description
Vertex Pharmaceuticals discovers and develops small-molecule and cell therapies, led by a dominant franchise in cystic fibrosis (Trikafta and predecessor CF modulators) and expanding into non-opioid pain, sickle cell disease, kidney disease (IgA nephropathy), type-1 diabetes, and — via the proposed Crinetics acquisition — rare endocrine disease. It is a rare example of a large-cap biotech with a near-monopoly in its base indication and a multi-front pipeline optionality story.
Competitive moat
Vertex owns the cystic fibrosis market outright: its CF modulators are the only disease-modifying therapies approved for the underlying protein defect, creating a durably priced franchise with essentially no generic or biosimilar substitution risk and a patient population that expands as label ages and genotypes broaden. The moat is now being extended rather than defended — Journavx (a peripherally acting non-opioid painkiller that blocks pain signalling before it reaches the brain) has no addictive potential, which is a structural differentiator versus opioids and could drive rapid share gains in acute pain. Casgevy, a one-time functional cure for sickle cell disease, adds a curative (higher-value, one-shot) model. A debt-free balance sheet and 2.65 current ratio fund pipeline investment and the Crinetics deal.
Recent developments
- Strong Q2 2026 (reported 08/04/2026): Revenue +12% Y/Y to USD 3.3B on the CF franchise plus accelerating new products; full-year 2026 revenue guidance raised to USD 13.1B-13.2B.
- Journavx launch: FDA approval of the non-opioid acute pain therapy positions Vertex in a market historically dominated by opioids, with CFRA expecting rapid uptake.
- Crinetics acquisition proposed: Would establish a fifth therapeutic pillar in rare endocrine diseases, diversifying beyond CF.
- Pipeline milestones: FDA accepted the filing for povetacicept in IgA nephropathy (IgAN); clearance to begin trials for a universal donor cell therapy in type-1 diabetes.
- CF franchise still growing: Trikafta upside remains via expansion of the treatable population, while Casgevy builds as a long-duration sickle cell opportunity.
Investment risks / red flags
- Pipeline dependence is rising: Valuation is increasingly tied to renal (povetacicept) and pain (Journavx) execution — any clinical or regulatory disappointment hits the multiple, which sits at 26x FY 26E.
- Binary clinical/regulatory risk typical of biotech: negative study news or unfavourable rulings.
- Pricing and reimbursement pressure, particularly for high-cost CF and cell/gene therapies.
- Emerging competitive threats in CF and in non-opioid analgesia.
- Concentration: revenue is still heavily weighted to a single therapeutic area, so CF pricing or access changes matter disproportionately.
Market Data
Source: mkts.io · Nov 19, 2026, 20:01 UTC
Key Metrics
Analyst Consensus
Calendar Events
Financials
Forward Estimates
| Period | EPS Est | Rev Est |
|---|---|---|
| 0q | 4.10 | $3.50B |
| +1q | 4.68 | $3.44B |
| 0y | 18.14 | $13.26B |
| +1y | 19.92 | $14.65B |
Earnings
Rating Changes
| Date | Firm | Action | To |
|---|---|---|---|
| Nov 4, 2026 | Barclays | main | Overweight |
| Nov 3, 2026 | JP Morgan | main | Overweight |
| Nov 3, 2026 | Goldman Sachs | main | Buy |
| Nov 3, 2026 | Morgan Stanley | main | Overweight |
| Nov 3, 2026 | Scotiabank | main | Sector Outperform |
| Nov 3, 2026 | UBS | main | Buy |
